Trump noncommittal to continued Taiwan arms sales after meeting with Xi

Trump said he is still deliberating a $14 billion arms sale to Taiwan approved by Congress in January, leaving the deal in doubt after his meeting with Xi Jinping. He also declined to commit to defending Taiwan in the event of a Chinese attack, reinforcing policy uncertainty around U.S.-China-Taiwan relations. The comments raise geopolitical risk for defense and Taiwan-related assets and could signal a notable shift in U.S. foreign policy.

Analysis

This is less about the arms package itself than about the signal it sends to allies and adversaries: policy conditionality is now explicitly a bargaining chip. The near-term market impact should show up first in U.S. primes and Taiwan-linked defense suppliers, but the second-order effect is more important — procurement timing risk increases, and that can compress booking visibility for contractors that depend on foreign military sales as a growth bridge between domestic budget cycles.

The bigger winner is likely the broader Chinese industrial ecosystem if this evolves into a de-escalation gesture. Even a partial softening on Taiwan support would strengthen Beijing’s conviction that economic engagement can buy strategic latitude, which raises the probability of a quieter regulatory environment for cross-border tech, autos, and capital flows over the next 3-12 months. For defense names, the risk is not canceled demand; it is delay risk and lower expected conversion rates on already-approved packages, which tends to hit sentiment before it hits revenue.

The tail risk is that this turns into a transactional precedent: if one arms sale is perceived as negotiable, future approvals for Taiwan and potentially Japan/Philippines-related deterrence packages become harder to underwrite politically. That would be bearish for U.S. defense multiples because it introduces policy beta into what had been treated as quasi-sticky backlog. On the flip side, if Washington quickly restates support or the administration approves the deal unchanged within weeks, the market likely reverses the move because the headline risk is doing more damage than any direct earnings impact.

Contrarian view: the consensus may be overstating the immediate revenue hit and understating the probability of a headline-only retreat. Congress already approved the deal, and defense contractors have long lead times, so the first-order earnings effect is small unless the administration actively slows export licensing. The better trade is to position for volatility rather than a clean directional break.

Key Decisions for Investors

• Buy short-dated puts on RTX and LMT into any strength over the next 1-3 weeks; the trade is for policy-vol compression rather than fundamental deterioration, with upside if the administration delays or reopens review of Taiwan-related sales.
• Pair trade: short a Taiwan/Asia defense proxy basket against long U.S. prime contractors only if the administration reaffirms support; otherwise reverse it and use the pair to isolate headline risk from broader defense spending.
• For a cleaner event hedge, buy 1-2 month straddles on RTX or NOC; implied vol should remain underpinned by policy uncertainty, and the payoff is best if the White House either reverses course or confirms a softer stance.
• Avoid chasing Chinese ADR upside immediately; if policy rhetoric softens, the better expression is via cyclicals with direct China revenue exposure over 3-6 months, not through broad EM beta, because the market will first demand proof of follow-through.
• Watch for a quick policy clarification within 5-10 trading days; if the sale is approved unchanged, cover defense shorts immediately because the setup becomes a failed headline trade rather than a durable thesis.